MM-120 Emerging Drug Insight and Market Forecast - 2032

“MM-120 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about MM-120 for Generalized Anxiety Disorder (GAD) in the seven major markets. A detailed picture of the MM-120 for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the MM-120 for Generalized Anxiety Disorder. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MM-120 market forecast, analysis for Generalized Anxiety Disorder in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Generalized Anxiety Disorder.

Drug Summary

MM-120 is MindMed's proprietary drug candidate, which is a pharmacologically optimized form of lysergic acid diethylamide (LSD; it has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions). The drug is a psychedelic drug which is being developed for GAD and other brain-based disorders and can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM-120 manifests primarily in visual as well as auditory hallucinations.

In August 2022, the company initiated patient dosing in the Phase IIb dose-optimization study of MM-120 for the treatment of GAD. Patient enrollment is currently ongoing, and topline results are expected in late 2023.

The Company continues to prioritize and focus its current development efforts and resources on MM-120 in psychiatric indications. MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and is aggressively protecting and expanding its intellectual property portfolio.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MM-120 description, mechanism of action, dosage and administration, research and development activities in Generalized Anxiety Disorder.
• Elaborated details on MM-120 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MM-120 research and development activity in Generalized Anxiety Disorder in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MM-120.
• The report contains forecasted sales of MM-120 for Generalized Anxiety Disorder till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Generalized Anxiety Disorder.
• The report also features the SWOT analysis with analyst views for MM-120 in Generalized Anxiety Disorder.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MM-120 Analytical Perspective

In-depth MM-120 Market Assessment

This report provides a detailed market assessment of MM-120 in Generalized Anxiety Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of MM-120.

MM-120 Clinical Assessment

The report provides the clinical trials information of MM-120 in Generalized Anxiety Disorder covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Generalized Anxiety Disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MM-120 dominance.
• Other emerging products for Generalized Anxiety Disorder are expected to give tough market competition to MM-120 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MM-120 in Generalized Anxiety Disorder.
• This in-depth analysis of the forecasted sales data of MM-120 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MM-120 in Generalized Anxiety Disorder.  

Key Questions Answered

• What is the product type, route of administration and mechanism of action of MM-120?
• What is the clinical trial status of the study related to MM-120 in Generalized Anxiety Disorder and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MM-120 development?
• What are the key designations that have been granted to MM-120 for Generalized Anxiety Disorder?
• What is the forecasted market scenario of MM-120 for Generalized Anxiety Disorder?
• What are the forecasted sales of MM-120 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Generalized Anxiety Disorder and how are they giving competition to MM-120 for Generalized Anxiety Disorder?
• Which are the late-stage emerging therapies under development for the treatment of Generalized Anxiety Disorder?

This product will be delivered within 2 business days.